Canopy Growth (CGC) Common Equity (2017 - 2026)
Canopy Growth (CGC) reported Common Equity of $508.7 million for Q1 2026, up 52.52% on a YoY basis from $333.5 million in Q1 2025, and down 5.05% sequentially from $535.8 million in Q4 2025.
Canopy Growth (CGC) Common Equity (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Common Equity data on file, last reported at $508.7 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 52.52% year-over-year to $508.7 million; the trailing twelve-month figure through Mar 2026 stood at $508.7 million (up 52.52% YoY), and the FY2026 full-year result was $508.7 million, up 52.52% from the prior year.
- Common Equity fell to $508.7 million in Q1 2026, from $535.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $2.8 billion in Q1 2022 to a low of $297.3 million in Q1 2024.
- A 5-year average of $709.5 million and a median of $523.7 million in 2025 frame the typical range for Common Equity.
- Across the five-year window, Common Equity tumbled 80.15% in 2023 and jumped 53.86% in 2025, its largest moves.
- Tracing CGC's Common Equity over 5 years: stood at $998.1 million in 2022, then slumped by 60.63% to $393.0 million in 2023, then grew by 1.65% to $399.4 million in 2024, then jumped by 34.13% to $535.8 million in 2025, then fell by 5.05% to $508.7 million in 2026.
- Business Quant data shows CGC's Common Equity at $508.7 million in Q1 2026, $535.8 million in Q4 2025, and $523.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 508.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 508.69 Mn |
| Dec 31, 2025 | 535.76 Mn |
| Sep 30, 2025 | 523.68 Mn |
| Jun 30, 2025 | 344.25 Mn |
| Mar 31, 2025 | 333.52 Mn |
| Dec 31, 2024 | 399.44 Mn |
| Sep 30, 2024 | 340.37 Mn |
| Jun 30, 2024 | 341.53 Mn |
| Mar 31, 2024 | 297.27 Mn |
| Dec 31, 2023 | 392.98 Mn |
| Sep 30, 2023 | 543.53 Mn |
| Jun 30, 2023 | 630.93 Mn |
| Mar 31, 2023 | 562.19 Mn |
| Dec 31, 2022 | 998.12 Mn |
| Sep 30, 2022 | 1.19 Bn |
| Jun 30, 2022 | 1.29 Bn |
| Mar 31, 2022 | 2.83 Bn |
| Dec 31, 2021 | 3.29 Bn |
| Sep 30, 2021 | 3.37 Bn |
| Jun 30, 2021 | 3.37 Bn |